Table 2.
Effectiveness of first-line antiretroviral therapy at 6, 12, and 24 months from start of antiretroviral therapy (ART) stratified by regimen and calendar year
| |
|
6 months |
12 months |
24 months |
|---|---|---|---|---|
| Overall | N (%) | N (%) | N (%) | |
| |
For patients with HIV VL |
754/980 (76.9) |
802/1054 (76.1) |
637/938 (67.9) |
| |
Best-case scenarioa |
1085/1311 (82.8) |
1059/1311 (80.8) |
1010/1311 (77.0) |
| |
Worst-case scenariob |
754/1311 (57.5) |
802/1311 (61.2) |
637/1311 (48.6) |
|
Stratified by type of ART regimen |
|
|
|
|
|
NNRTI-based |
|
|
|
|
| |
For patients with HIV VL |
583/740 (78.8) |
603/784 (76.9) |
503/711 (70.7) |
| |
Best-case scenario |
830/987 (84.1) |
806/987 (81.7) |
779/987 (78.9) |
| |
Worst-case scenario |
583/987 (59.1) |
603/987 (61.1) |
503/987 (51.0) |
|
PI-based |
|
|
|
|
| |
For patients with HIV VL |
171/240 (71.3) |
199/270 (73.7) |
134/227 (59.0) |
| |
Best-case scenario |
255/324 (78.7) |
253/324 (78.1) |
231/324 (71.3) |
| |
Worst-case scenario |
171/324 (52.8) |
199/324 (61.4) |
134/324 (41.4) |
|
Stratified by calendar year of ART initiation |
|
|
|
|
|
2000-2004 |
|
|
|
|
| |
For patients with HIV VL |
157/252 (62.3) |
188/297 (63.3) |
171/287 (59.6) |
| |
Best-case scenario |
297/392 (75.8) |
283/392 (72.2) |
276/392 (70.4) |
| |
Worst-case scenario |
157/392 (40.1) |
188/392 (48.0) |
171/392 (43.6) |
|
2005-2010 |
|
|
|
|
| |
For patients with HIV VL |
597/728 (82.0) |
614/757 (81.1) |
466/651 (71.6) |
| |
Best-case scenario |
788/919 (85.7) |
776/919 (84.4) |
734/919 (79.9) |
| Worst-case scenario | 597/919 (65.0) | 614/919 (66.8) | 466/919 (50.7) | |
HIV: human immunodeficiency virus, VL: viral load, PI: protease inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor.
aBest-case scenario assumes missing viral load data as suppression.
bWorst-case scenario assumes missing viral loads data as failures.